Loading ...
Sorry, an error occurred while loading the content.
 

NATAP: PEGASYS + Ribavirin: New England Journal Study

Expand Messages
  • claudine intexas
    NATAP - www.natap.org PEGASYS + Ribavirin: New England Journal Study Here is a more detailed report I wrote following the DDW Conference presentation of this
    Message 1 of 1 , Sep 26, 2002
      NATAP - www.natap.org

      PEGASYS + Ribavirin: New England Journal Study

      Here is a more detailed report I wrote following the DDW Conference
      presentation of this study by Mike fried, MD, the chief study
      investigator. In addition, what is not in this report was the results
      broken down by genotype and viral load so here it is. For genotype 1
      with >2 million viral load pegasys+RBV resulted in 41% SVR vs 33% for
      IFN+RBV. For genotype 2 there was not much difference between high or
      low viral load: >2 million -74% SVR for Pegasys/RBV vs 59% SVR for
      IFN/RBV; <2 million - 81% SVR for Pegasys/RBv vs 65% SVR for IFN/RBV.

      Pegylated (40kDa) Interferon Alfa-2a (Pegasys) in Combination With
      Ribavirin: efficacy and Safety Results From a Phase III Randomized,
      Actively Controlled Multicenter Study

      http://www.natap.org/2001/ddw/pegylated052301.htm


      __________________________________________________
      Do you Yahoo!?
      New DSL Internet Access from SBC & Yahoo!
      http://sbc.yahoo.com
    Your message has been successfully submitted and would be delivered to recipients shortly.